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Abstract
Background: Cachexia is associated with increased mortality risk among chronic obstructive pulmonary disease
(COPD) patients. However, low body mass index (BMI) as opposed to cachexia is often used, particularly when
calculating the BODE (BMI, Obstruction, Dyspnea and Exercise) index. For this reason, we examined mortality using
a consensus definition and a weight-loss definition of cachexia among COPD cases and compared two new COPD
severity indices with BODE.
Methods: In the current report, the consensus definition for cachexia incorporated weight-loss > 5% in 12-months
or low BMI in addition to 3/5 of decreased muscle strength, fatigue, anorexia, low FFMI and inflammation.
The weight-loss definition incorporated weight-loss > 5% or weight-loss > 2% (if low BMI) in 12-months. The
low BMI component in BODE was replaced with the consensus definition to create the CODE (Consensus
cachexia, Obstruction, Dyspnea and Exercise) index and the weight-loss definition to create the WODE (Weight loss,
Obstruction, Dyspnea and Exercise) index. Mortality was assessed using Kaplan-Meier survival and Cox Regression.
Performance of models was compared using C-statistics.
Results: Among 1483 COPD cases, the prevalences of cachexia by the consensus and weight-loss definitions were 4.7
and 10.4%, respectively. Cachectic patients had a greater than three-fold increased mortality by either the consensus or
the weight-loss definition of cachexia independent of BMI and lung function. The CODE index predicted mortality
slightly more accurately than the BODE and WODE indices.
Conclusions: Cachexia is associated with increased mortality among COPD patients. Monitoring cachexia using
weight-loss criteria is relatively simple and predictive of mortality among COPD cases who may be missed if only low
BMI is used.
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Background
Cachexia is characterized by a rapid weight-loss, primar-
ily caused by loss of muscle with or without loss of fat,
in individuals suffering from a chronic illness [1].
Though the precise definition of cachexia is controver-
sial, it is generally agreed that cachexia is associated with
a greatly increased risk of mortality among COPD cases
[2, 3]. By general population prevalence, it has been
estimated that there are 1.4 times as many cases with
cachexia in COPD compared to cancer cases [4]. Import-
ant systemic manifestations of COPD may be captured
using the well-established BODE (BMI, Obstruction,
Dyspnea and Exercise) index, which ranges from 0 to
10 [5, 6]. COPD patients with higher BODE scores have
a higher risk of death and the index outperforms the
mortality prediction of its individual components which
includes low BMI (BMI < 21) [5]. However, patients
across the entire BMI spectrum may be at risk of devel-
oping cachexia [7, 8]. Evaluating COPD cachexia using
only BMI may underdiagnose overweight patients as it
may mask significant muscle wasting [7, 8].
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The current consensus definition for cachexia diagnosis
among COPD, heart failure, and cancer cases incorporates
weight-loss > 5% in the last 12months in addition to three
out of five criteria: 1) decreased muscle strength; 2)
fatigue; 3) anorexia; 4) low fat-free mass index (FFMI);
and 5) evidence of increased inflammatory markers (C-re-
active protein (CRP), interleukin-6 (IL6), etc.), anemia or
low serum albumin [1]. A challenge for studying cachexia
in COPD is that most often all of the criteria for the
consensus definition are not available as part of routine
clinical care nor in large epidemiologic cohorts. Re-
cently, cachexia was characterized among cancer cases
using simpler criteria (weight-loss > 5% or, if low BMI,
weight-loss > 2%) than the consensus definition [9].
As the current estimates of COPD cachexia have been
largely based on low BMI, we aimed to estimate the preva-
lence of cachexia and its associated mortality in a large co-
hort of COPD cases followed for three years in the
ECLIPSE study using two sets of cachexia criteria that we
termed consensus and weight-loss (Table 1). The consen-
sus criteria used in the current analyses differed from the
standard consensus definition of cachexia in that informa-
tion was not available to assess muscle strength or all
components of abnormal biochemistry [1]. Low 6-min
walk distance (6MWD) was used as a surrogate for re-
duced muscle strength. We further aimed to examine the
prevalence of cachexia stratified by severity of COPD and
BMI category. We hypothesized that COPD cases with
cachexia would have an increased risk of mortality. We
further hypothesized that cachexia would be more com-
mon among more severe COPD cases as defined by
GOLD stage but would be prevalent across all categories
of BMI (low to obese). We also replaced the low BMI
component of BODE with the criteria for consensus and
weight-loss cachexia to create the CODE (Cachexia,
Obstruction, Dyspnea and Exercise) and WODE (Weight
loss, Obstruction, Dyspnea and Exercise) indices and com-
pared performance in terms of mortality prediction.
Methods
Study population
The ECLIPSE (Evaluation of COPD Longitudinally to
Identify Predictive Surrogate Endpoints) datasets analyzed
during the current study are available in the database of
genotypes and phenotypes (dbGaP) as phs001252.v1.p1
(https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.
cgi?study_id=phs001252.v1.p1). All analyses were per-
formed after obtaining approval from the Institutional Re-
view Board of the University of Alabama at Birmingham.
ECLIPSE (SCO104960, NCT00292552, www.eclipse-copd.
com), which has been described in detail elsewhere [10],
was a non-interventional, observational, multicenter study
which followed COPD patients and controls that were ei-
ther nonsmokers or who had a smoking history of ≥10
pack-years, aged 45–75 years from 46 centers across 12
countries over 3 years with 8 visits.
In total,1825 ECLIPSE participants with COPD at both
baseline and Year 1 met consent criteria for the current
analyses (Additional file 1: Figure S1). At Year 1, 1483
COPD cases were assessed for the consensus definition
of cachexia, and weight-loss associated with cachexia
(Additional file 1: Figure S1). Only COPD cases with
data available to characterize both cachexia traits were
included in the current analyses. COPD was diagnosed
using standardized post-bronchodilator spirometry at
both baseline and Year 1 of the study. Percent weight-
loss was calculated by subtracting the Year 1 weight
from baseline weight at study entry, dividing by the
baseline weight and multiplying by 100. Participants
who exhibited weight-loss exceeding threshold values
(weight-loss more than 5% or if BMI < 20 kg/m2 and
weight-loss more than 2%) at Year 1 with evidence that
weight was regained at a later visit between Years 1 and
3 in the study were coded as not having weight-loss.
FFMI was measured using bioelectrical impedance. Low
FFMI was classified if FFMI was below the 5th percentile
value in age, BMI and sex-stratified data from healthy
individuals in the UK Biobank [11]. Low BMI was de-
fined as BMI < 20 kg/m2. 6MWD less than 350m [12]
was used as a surrogate for reduced muscle strength (see
Discussion). Fatigue was classified by Functional Assess-
ment of Chronic Illness Therapy (FACIT) score less than
34 [13]. Anorexia was classified if a participant reported
they did not feel like eating in the last week for 3 or
more days. Abnormal biochemistry was defined as
CRP > 5 mg/L or anemia (hemoglobin < 12 g/dL). All
variables used for coding the cachexia traits were collected
at the Year 1 visit, with the exception of fatigue and
anorexia, which were only collected at baseline. Two new
indexes, the WODE and CODE, were coded by replacing
the BMI component of BODE with weight-loss cachexia
or consensus cachexia, respectively.
Statistical analysis
All analyses were performed using the statistical soft-
ware R. The chi-square test of homogeneity was used to
test for differences between categorical variables. The
two-sided student’s t-test was used to test for differences
Table 1 Criteria used to define cachexia by either consensus or
weight-loss definitions among COPD cases in ECLIPSE
Definition Criteria
Consensus Weight-loss > 5% in 12-months or low BMI in addition
to 3 out of 5 of decreased muscle strength, fatigue,
anorexia, FFMI and abnormal biochemistry (hemoglobin
12 g/dL or CRP > 5mg/L)
Weight-loss Weight-loss > 5%, or, in the presence of low BMI,
weight-loss > 2%
FFMI fat-free mass index, CRP C-reactive protein, BMI body mass index
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between continuous variables. The Cochran Armitage
test for trend was used to assess trends in the prevalence
of cachexia and weight-loss with categorical variables.
Survival modeling was performed using Kaplan-Meier
curves and Cox proportional hazards regression. Cox
proportional hazards models included adjustment for
continuous variables age and smoking duration (pack-
years) and categorical variables sex and BMI category
(low < 18.5 kg/m2, normal between 18.5 kg/m2 and
25 kg/m2, overweight between 25 kg/m2 and 30 kg/m2
and obese > 30 kg/m2). BMI category was classified based
on Year 1 BMI even in those who changed BMI category
during the mortality follow-up. Mortality prediction
accuracy of each of three indices (BODE, CODE and
WODE) was evaluated by calculating C-statistics.
Results
Study characteristics
A total of 1483 COPD cases from the ECLIPSE study
with complete information available to classify consen-
sus and weight-loss cachexia (Table 1) were included in
the analysis. Among the COPD cases analyzed, there
were more men (65.3%) than women. The median age
was 64 years and the median BMI was 25.9 (Table 2).
COPD cases had median smoking history of 44
pack-years and were distributed in GOLD spirometry
grades 2 through 4, which were previously referred to as
“GOLD stages” (Table 2). COPD cases included in our
analyses differed from those excluded due to missing in-
formation for coding consensus or weight-loss cachexia
with respect to age and severity of COPD defined by
FEV1% predicted and GOLD stage (Table 2). COPD
cases excluded from analyses were on average older and
comprised of more severe cases with respect to lung
function.
Prevalence of cachexia and weight-loss among COPD cases
Among COPD cases, the prevalence of cachexia using
the consensus definition was 4.7% and using the
weight-loss definition was 10.4%. When the results were
stratified by GOLD stage, the percentage of COPD cases
with cachexia by the consensus definition significantly
(p < 0.001) increased with increasing GOLD stage
(Fig. 1a). Similarly, the percentage of COPD cases with
cachexia by the weight-loss definition significantly (p <
0.05) increased with increasing GOLD stage (Fig. 1b).
When the results were stratified by BMI category (normal,
overweight, obese and low), COPD cases with low BMI
were more likely (p < 0.001) to have cachexia by both the
consensus and weight-loss definitions (Fig. 1c and d). How-
ever, there were cachectic COPD cases as defined by the
consensus and weight-loss definitions among all categories
of BMI. Participants with cachexia and weight-loss
had significantly (p < 0.001) more emphysema at base-
line and Year 1 (Additional file 2: Figure S2). There
was no significant change in emphysema over Year 1
among COPD participants with cachexia and weight-
loss (Additional file 3: Figure S3).
Overlap in classification and relationship with mortality of
cachexia among COPD cases
A total of 12.1% of COPD cases met the criteria for
cachexia by the consensus or weight-loss definitions
(Fig. 2). A total of 3.0% of COPD cases were classified as
cachectic by both the consensus and weight-loss defini-
tions of cachexia. In our analysis using longitudinal
follow-up data, there were 72 deaths. The median
follow-up time for the cohort was 2.9 years. COPD cases
with cachexia by the consensus or weight-loss definition
were more likely to die than those without cachexia
(Fig. 3a, b, c). We further examined the relationships
between cachexia and all-cause mortality using Cox re-
gression modeling accounting for pack-years of smoking,
BMI category, sex and age. When controlling for these
additional covariates, cachexia by the consensus defin-
ition was still associated with an increased risk of death
(Table 3 Consensus: Model Hazard Ratio (HR): 3.2,
95% CI 1.6–6.6, p = 0.001). This observation also held
when cachexia was defined using the weight-loss def-
inition (Table 3: Weight-Loss Model HR: 3.2 95% CI:
1.8–5.6, p < 0.001). Similarly, COPD subjects with either
cachexia by the consensus definition or weight-loss were
at an increased risk of death (Table 3: Consensus or
Weight-Loss Model HR: 2.9, 95% CI 1.7–5.1, p < 0.001). In
the Cox Proportional models, we also observed a
Table 2 Characteristics of ECLIPSE Study COPD cases included
and excluded from analyses
Descriptive COPD Cases
Included
COPD Cases
Excluded
P-value
N 1483 342
Sex (% Male) 65.3 67 0.6
Age 64 (10) 66 (11) 0.04
BMI 25.9 (7.1) 25.6 (6.2) 0.1
Current Smoking (%) 44 (29) 44 (26) 0.9
FEV1 (% predicted) 47.5 (23.5) 44.2 (28.9) 0.02
GOLD 2 (%) 44.9 38 0.04
GOLD 3 (%) 41.1 44.2
GOLD 4 (%) 14 17.8
N total number, IQR interquartile range, BMI body mass index
Notes: The chi-square test of homogeneity was used to test for differences
between categorical variables. The two-sided student’s t-test was used to test
for differences between continuous variables. All variables were measured at
Year 1 Visit, with the exception of pack-years, which was based on the
baseline visit
COPD cases were excluded if missing information necessary to code the
consensus or weight-loss cachexia traits. Continuous variables (age, BMI,
FEV1% predicted) are represented by median (IQR). Significant p-values
are bolded
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significant reduced risk of death for overweight COPD pa-
tients in comparison with normal weight COPD patients
(Consensus Model Overweight HR: 0.30, 95% CI 0.14–
0.65, p = 0.002, Weight-Loss Model Overweight HR: 0.30,
95% CI 0.14–0.66, p = 0.003, Consensus or weight-loss
Model Overweight HR: 0.31, 95% CI 0.14–0.68, p = 0.003).
We contrasted the descriptives of overweight and normal
BMI COPD participants in Additional file 4: Table S1.
Overweight participants with COPD had better lung func-
tion defined by FEV1 percent predicted and fewer severe
cases based on GOLD. However, all GOLD stages were
represented among the overweight COPD cases. When
COPD cases with weight-loss between baseline and Year 1
regained the weight at a later visit were coded as meeting
the criteria for weight-loss, the increased risk of death as-
sociated with the consensus and weight-loss definitions
remained significant (Additional file 5: Table S2: Consen-
sus Model HR: 2.8 95% CI 1.4–5.7, p = 0.004, Weight-Loss
Model: HR: 2.4 95% CI: 1.4–4.2, p = 0.002, Consensus or
weight-loss Model HR: 2.3, 95% CI 1.3–4.0, P = 0.004) as
the significant relationship with decreased risk of death as-
sociated with being overweight.
Comparison of WODE and CODE indices with BODE
We coded two new indices, WODE and CODE by re-
placing the BMI component of BODE with either cachexia
defined by weight-loss or the consensus definition. COPD
cases with higher CODE scores were more likely to die
A B
C D
Fig. 1 Prevalence of cachexia (consensus and weight-loss definitions) stratified by GOLD and BMI category among COPD cases at Year 1 Visit in
ECLIPSE stratified by GOLD (a, b) and BMI category (c, d). Numbers above bars represent prevalence in each group. Percentage of COPD cases
with cachexia by the consensus definition significantly (p < 0.001) increased with increasing GOLD stage, COPD cases with low BMI were more
likely (p < 0.001) to have cachexia by both the consensus and weight-loss definitions. Note: Cochran Armitage test was used to assess trends
Fig. 2 Overlap in classification of consensus and weight-loss classifications among COPD cases in ECLIPSE
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than those with higher WODE or BODE scores. In the
ECLIPSE cohort, we also observed a more uniform in-
crease in risk of death for each increasing quartile for
CODE and WODE scores in comparison with BODE
(Fig. 4). We further assessed the precision of each metric
by comparing survival times and probability of death
using C-statistics. The C-statistics were comparable be-
tween all 3 indices (CBODE = 0.72, CWODE = 0.71, CCODE =
0.73). Further, the p-value from the Kaplan-Meier survival
based on CODE quartiles was also slightly more signifi-
cant than for BODE and WODE quartiles (Fig. 4).
Discussion
In the current investigation, the prevalence of cachexia
in COPD cases ranges from 4.7 to 10.4% depending on
the criteria used to define cachexia. Further, COPD cases
representative of the entire BMI spectrum, not just those
with low BMI, met the criteria for cachexia. Using either
consensus definition or a simpler definition based on
recent weight-loss, cachectic COPD cases were at an
approximately three-fold increased risk of death. This
increased risk of death was independent of BMI. These
findings differ from other studies indicating increased
risk of mortality for COPD patients with low BMI
because patients across all BMI categories had cachexia.
This underscores the importance of using more than
low BMI to monitor patients for cachexia. Although the
weight-loss definition of cachexia does not incorporate
several key components of the consensus definition, it is
comparatively simple to assess and highly predictive of
patient survival. When we replaced the BMI component
of BODE with either cachexia defined by weight-loss
(WODE) or the consensus (CODE) definitions, CODE
classified patients at risk of death slightly better than
WODE or BODE; however, the results were comparable
for all three indices. Our study has several strengths
including recruitment of a large sample size of COPD
patients with detailed phenotyping relevant to COPD
and cachexia. These strengths were complemented by a
relatively long follow-up period to examine survival and
the impact of regaining weight.
We report the first study to apply a consensus definition
of cachexia to a population of COPD cases to estimate
prevalence. In the current investigation, the consensus
and weight-loss definitions of cachexia demonstrated the
prevalence ranged from 4.7 to 10.4%. With respect to
cachexia defined by weight-loss, Barker et al. 2014 ob-
served 15% of COPD patients exhibited a weight-loss > 5%
A B C
Fig. 3 Kaplan Meier Survival Stratified by Cachexia as compared to the remaining cohort. a. Cachexia defined using consensus definition, b.
Cachexia defined by weight-loss and c. Cachexia defined as either consensus definition or weight-loss
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in 16months of follow-up which is similar to the rate ob-
served in the current investigation [14]. Whereas, the
prevalence of weight-loss was higher, 49%, in a cohort of
COPD patients admitted to a pulmonary rehabilitation
center [15]. Multiple sets of criteria of varying complexity
have been proposed for classifying cachexia ranging from
low BMI to the consensus definition. Patients with COPD
often develop other diseases including heart failure and
cancer [16] which also can lead to cachexia. Thus, we used
the majority of the criteria from the consensus definition
[1] to classify cachexia because it was developed by re-
searchers with expertise representative of several diseases
including COPD, heart failure and cancer. The consensus
definition of cachexia is currently the definition accepted
by the Society of Cachexia and Wasting Disorders [17].
We also observed in our Cox proportional hazards
models (Table 3) a reduced risk of death for overweight
COPD patients in comparison with normal weight
COPD patients. A related phenomenon is frequently
observed when examining BMI as a cross-sectional
measure in diseased populations and has been termed
the obesity paradox [18]. However, in our models, which
also included the consensus and weight-loss definitions
of cachexia in addition to known smoking duration,
FEV1pp, sex and age, the reduced risk was only associ-
ated with being overweight as opposed to obese. One
possible explanation for this observation which we ex-
plored was that a magnitude of weight-loss > 5% was not
large enough in this population to confer increased risk
of death. We ran models examining larger cut points of
weight-loss such as weight-loss > 10% and the finding
still held (data not shown). Landbo et al. 1999 [19] pre-
viously reported reduced risk of death associated with
increasing BMI among severe COPD patients and a
U-shaped risk profile among those with mild COPD. To
assess whether severity of COPD could explain our ob-
servation among overweight participants, we contrasted
descriptive characteristics between normal and over-
weight COPD participants (Additional file 4: Table S1)
and found all GOLD stages represented among the
Table 3 Relationships between risk of death from any cause with consensus and weight-loss definitions of cachexia in COPD cases
from ECLIPSE
Model Covariate HR (95% CI) P-value
Model 1 Consensus 3.2 (1.6–6.6) 0.001
Pack-years 1.0 (0.99–1.01) 0.1
BMI category (ref = Normal) Low 0.67 (0.23–2.0) 0.46
Overweight 0.30 (0.14–0.65) 0.002
Obese 1.5 (0.86–2.5) 0.16
Sex (ref = males) 0.86 (0.49–1.5) 0.49
Age 1.1 (1.0–1.1) < 0.001
FEV1% pred 0.98 (0.96–0.99) < 0.001
Model 2 Weight-loss 3.2 (1.8–5.6) < 0.001
Pack-years 1.0 (0.998–1.01) 0.17
BMI category (ref = Normal) Low 0.68 (0.24–2.0) 0.48
Overweight 0.30 (0.14–0.66) 0.003
Obese 1.5 (0.89–2.7) 0.12
Sex (ref = males) 0.78 (0.45–1.4) 0.39
Age 1.1 (1.0–1.1) < 0.001
FEV1% pred 0.97 (0.96–0.99) 0.003
Model 3 Consensus or weight-loss 2.9 (1.7–5.1) < 0.001
Pack-years 1.0 (0.998–1.01) 0.16
BMI category (ref = Normal) Low 0.62 (0.21–1.8) 0.39
Overweight 0.31 (0.14–0.68) 0.003
Obese 1.6 (0.91–2.7) 0.11
Sex (ref = males) 0.80 (0.46–1.4) 0.44
Age 1.07 (1.03–1.1) < 0.001
FEV1% pred 0.97 (0.96–0.99) 0.003
FEV1% pred: forced expiratory volume in 1 s percent predicted, BMI: body mass index
Significant p-values are bolded
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overweight participants. There were more GOLD 3 and
4 participants in the normal weight group in comparison
with the overweight group. For this reason, we adjusted
for FEV1% predicted in the Cox Proportional Hazards
Models; however, the relationship of reduced risk among
the overweight group holds (Table 3). Thus, this obser-
vation of reduced risk of death in the Cox Proportional
Hazards Models for COPD patients with overweight
BMI in comparison with normal BMI is likely the result
of unmeasured confounders more prevalent in the over-
weight population. It is important to note that there was
no significant difference in risk of death between the
obese BMI group in comparison with the normal weight
BMI group in the Cox Proportional Hazards Models.
Collectively, the survival models indicate cachexia and
weight-loss are associated with increased risk of death
independent of BMI group.
Our investigation has several weaknesses. One weak-
ness of the current study is we did not assess whether
weight-loss was unintentional. It is possible the observed
weight-loss in some individuals was intentional through
dieting and/or increased exercise. To alleviate this limi-
tation, we restricted weight-loss coding to those who did
not exhibit a re-gain in weight at a later visit over the 3
years of the study. Our logic was based on the unfortu-
nate fact that most diets fail and can be characterized by
re-gain of original weight lost [20, 21]. However, we also
performed a sensitivity analysis classifying cachexia with-
out removing those who regained weight later in the
study and still observed a statistically significant in-
creased risk of death for COPD cases with cachexia
(Additional file 1: Figure S1). A further weakness is that
we performed a secondary analysis of data primarily col-
lected to understand the etiology of COPD rather than
the etiology of cachexia. As a result, some of the criteria
used to code the consensus definition of cachexia were
not ideal which is why we refer to it as the consensus
definition throughout. More specifically, we used low
6MWD as a surrogate of reduced muscle strength
whereas the consensus definition recommends the use
of handgrip strength [1], which was not measured in the
current study. Low 6MWD is not a true measure of
muscle strength and more appropriately should be clas-
sified as an endurance test. However, 6MWD is com-
monly administered in epidemiologic studies of COPD
whereas strength measures are not. Low 6MWD likely
A B C
Fig. 4 Kaplan Meier Survival Comparison between. a. BODE b. WODE and c. CODE quartiles
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captures COPD cases with extremely reduced muscle
strength; however, it may misclassify others. Addition-
ally, all of the criteria to classify abnormal biochemistry
(increased CRP or IL6, anemia and low serum albumin)
were not available. In general, the bias introduced by
misclassification due to incomplete criteria for the con-
sensus definition was most likely towards the null as
more COPD cases with weight-loss would have been
coded as non-cachectic without the additional informa-
tion. Further our main results from the survival analyses
were consistent whether we defined cachexia using the
consensus or weight-loss definition of cachexia. Another
weakness is we do not know whether COPD cases in the
current study meet the criteria for cachexia due to
COPD as opposed to other diseases where cachexia is
prevalent such as heart failure and/or cancer. This is one
of the reasons that we elected to evaluate cachexia using
as much information as possible based on the consensus
definition developed by researchers with expertise repre-
sentative of several diseases including COPD, heart fail-
ure and cancer.
Conclusion
In summary, we report the first study of cachexia using
a consensus definition of cachexia among COPD cases.
Our investigation revealed the prevalence of cachexia
among COPD cases was lower than estimates using only
low BMI and low FFMI. Importantly, COPD cases across
the entire BMI spectrum were at risk for cachexia which
dispels the notion of cachexia being captured exclusively
by low BMI. Despite the lower prevalence of cachexia
observed using the consensus and weight-loss definitions
in the ECLIPSE study, cachectic COPD cases were at a
considerably increased risk of death. Monitoring unin-
tentional weight-loss among COPD cases is relatively
simple and indicative of patient prognosis. Increased
awareness and tracking of weight-loss may facilitate
enrolment in clinical trials testing exercise, pharmaco-
logical or nutritional intervention in this at-risk popula-
tion. Future efforts will be directed at recruiting cohorts
of COPD cases phenotyped for cachexia in order to fur-
ther elucidate the etiology of cachexia and expand our
understanding of patient prognosis.
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